Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective allowing therapies to reach the tumor.
In addition to our proprietary product portfolio, Halozyme has value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly for our ENHANZE™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. We are headquartered in San Diego.
Closing share price
|FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$54.8 m||$75.3 m||$135.1 m||$146.7 m|
Revenue growth, %
|$48.6 m||$52.6 m||$105.8 m|
Operating expense total
|$129 m||$115.6 m||$133.3 m|
|($80.4 m)||($63 m)||($27.5 m)|
|($83.5 m)||($68.4 m)||($32.2 m)||($103 m)|
Operating cash flow
|($72.1 m)||$34 m||($18.1 m)|